Biomerieux SA (BIM)
Euronext Paris · France · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 89.20 |
|---|---|
| 52-week range | 65.60 – 116.10 |
| Return, 1 month / 3 months | +19.1% / +29.3% |
| Return, 1 year / 3 years | −20.5% / +5.2% |
| Trend | Uptrend |
| RSI (14) | 77 |
| Volatility (1 year) | 31.1% |
| Worst drawdown (1 year) | -41.2% |
| Average daily value traded | 12.80M EUR |
| Dividend yield | 1.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
BioMerieux is a French in vitro diagnostics company based near Lyon. It develops and makes diagnostic tests, reagents and laboratory instruments used by hospitals, clinical laboratories and industry. Its work focuses on clinical microbiology, infectious disease testing, immunoassays and industrial quality control of food, pharmaceuticals and cosmetics. The company supplies systems for identifying bacteria, testing blood cultures and detecting infections, helping laboratories diagnose disease and monitor treatment.
On this site Biomerieux SA appears as a stock on the Euronext Paris (France), code BIM, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Biomerieux SA (BIM) trades on the Euronext Paris in France. It last closed at EUR 89.20 on 23 October 2026.
Its price-based Market X-Ray is 64 out of 100 (a fair price profile), ranking 169 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 20.5% and over the last three months it rose 29.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 10.8% | ||
| From 52-week high | -22.3% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 29.3% | ||
| 6-month return | 23.4% | ||
| 12-month return, skipping the last month | -33.2% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -41.2% | ||
| Liquidity | 91 · Strong | Trades actively. | |
| Average daily value traded | 12.80M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 33 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.1% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +2.2% |
|---|---|
| 1 month | +19.1% |
| 3 months | +29.3% |
| 6 months | +23.4% |
| 1 year | −20.5% |
| 3 years | +5.2% |
| 5 years | −10.3% |
Signals
| 50-day / 200-day average | 77.48 / 80.47 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.84 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 Jun 2026 | EUR 0.9800 |
| 9 Jun 2025 | EUR 0.9000 |
| 7 Jun 2024 | EUR 0.8500 |
| 6 Jun 2023 | EUR 0.8500 |
| 6 Jun 2022 | EUR 0.8500 |
| 4 Jun 2021 | EUR 0.6200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.